Cardurion Pharmaceuticals, a cutting-edge cardiovascular company specializing in the development of innovative therapeutics for heart failure and other cardiovascular ailments, announced a successful funding round that raised an impressive $260 million. The company, spearheaded by a dedicated team of cardiovascular experts and seasoned industry professionals, is diligently working on revolutionary clinical programs focusing on PDE9 and CaMKII inhibition. The substantial investment, including an exceptional $300 million contribution from Bain Capital, will be channeled towards advancing ongoing initiatives, bolstering the current pipeline, and driving future growth endeavors. Cardurion Pharmaceuticals, with operational bases in Burlington, Massachusetts, and Shonan, Japan, aims to leverage this significant funding to further solidify its position as a trailblazer in cardiovascular therapeutics. To learn more about Cardurion Pharmaceuticals and its groundbreaking work, please visit their website at http://www.cardurion.com.
The Future of Heart Health: Cardurion Pharmaceuticals Raises $260 Million in Series B Funding
Recently funded 路 $260.0M Series bHealthcare
Get the full Cardurion Pharmaceuticals company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
